JP2006515587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515587A5 JP2006515587A5 JP2004560041A JP2004560041A JP2006515587A5 JP 2006515587 A5 JP2006515587 A5 JP 2006515587A5 JP 2004560041 A JP2004560041 A JP 2004560041A JP 2004560041 A JP2004560041 A JP 2004560041A JP 2006515587 A5 JP2006515587 A5 JP 2006515587A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- composition
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- LUANXJIOUGKVRZ-UWVGGRQHSA-N (2s,4s)-4-(3-chlorophenoxy)pyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@@H]1OC1=CC=CC(Cl)=C1 LUANXJIOUGKVRZ-UWVGGRQHSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- -1 hept-3-yl Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43349102P | 2002-12-13 | 2002-12-13 | |
| PCT/IB2003/005682 WO2004054563A1 (en) | 2002-12-13 | 2003-12-03 | Alpha-2-delta ligand for the treatment of sexual dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006515587A JP2006515587A (ja) | 2006-06-01 |
| JP2006515587A5 true JP2006515587A5 (enExample) | 2006-10-12 |
Family
ID=32595199
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004560041A Withdrawn JP2006515587A (ja) | 2002-12-13 | 2003-12-03 | 性的不能を治療する方法 |
| JP2004560036A Pending JP2006511527A (ja) | 2002-12-13 | 2003-12-03 | 種々の薬学的用途のためのα２δリガンド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004560036A Pending JP2006511527A (ja) | 2002-12-13 | 2003-12-03 | 種々の薬学的用途のためのα２δリガンド |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US7432299B2 (enExample) |
| EP (2) | EP1572183A1 (enExample) |
| JP (2) | JP2006515587A (enExample) |
| KR (2) | KR100703103B1 (enExample) |
| CN (8) | CN100367946C (enExample) |
| AU (3) | AU2003303038B2 (enExample) |
| BR (2) | BR0316753A (enExample) |
| CA (3) | CA2451267A1 (enExample) |
| MX (2) | MXPA05006318A (enExample) |
| MY (1) | MY140525A (enExample) |
| NZ (2) | NZ566452A (enExample) |
| PL (2) | PL377729A1 (enExample) |
| TW (2) | TWI286934B (enExample) |
| WO (3) | WO2004054559A1 (enExample) |
| ZA (6) | ZA200503862B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| US20050043345A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| CA2539976A1 (en) | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | Therapeutic beta aminoacids |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| WO2006002262A2 (en) | 2004-06-21 | 2006-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
| DK1791423T3 (da) * | 2004-08-02 | 2013-08-05 | Sami Labs Ltd | Sammensætninger og fremgangsmåder til behandling af hyperproliferative dermatologiske tilstande |
| ES2393768T3 (es) | 2005-05-26 | 2012-12-27 | Neuron Systems, Inc | Derivado de quinolina para el tratamiento de enfermedades retinianas |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| WO2007027476A2 (en) * | 2005-08-26 | 2007-03-08 | Xenoport, Inc. | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
| DE102005050377A1 (de) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| EA200970487A1 (ru) * | 2006-12-08 | 2009-12-30 | Ксенопорт, Инк. | Применение пролекарств аналогов гамк для лечения заболеваний |
| DE102007001804A1 (de) * | 2007-01-12 | 2008-07-17 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung von GABAB-Rezeptor selektiven Agonisten zur Behandlung entzündlicher Hauterkrankungen |
| CA2703472A1 (en) * | 2007-10-26 | 2009-04-30 | The Scripps Research Institute | Methods for treating substance dependence |
| CA2704428C (en) * | 2007-11-02 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Fgf9-related methods for treating anxiety |
| JP5563483B2 (ja) * | 2008-01-25 | 2014-07-30 | ゼノポート，インコーポレイティド | アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解 |
| US7872046B2 (en) * | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| SG157299A1 (en) * | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN102432525A (zh) * | 2011-10-20 | 2012-05-02 | 苏州康润医药有限公司 | 3-苄基-3-氮杂二环[2,1,0]己烷的实用合成方法 |
| WO2014100425A1 (en) | 2012-12-20 | 2014-06-26 | Aldexa Therapeutics, Inc. | Peri-carbinols |
| US8992951B2 (en) * | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| HK1217439A1 (zh) | 2013-01-23 | 2017-01-13 | Aldeyra Therapeutics, Inc. | 与毒性醛相关的疾病和治疗 |
| HK1217490A1 (zh) | 2013-01-25 | 2017-01-13 | Aldeyra Therapeutics, Inc. | 黃斑變性治療中的新穎捕獲劑 |
| US10610512B2 (en) | 2014-06-26 | 2020-04-07 | Island Breeze Systems Ca, Llc | MDI related products and methods of use |
| EP3294391A1 (en) * | 2015-05-12 | 2018-03-21 | Cipla Europe NV | Inhaler device |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| MX2018013472A (es) | 2016-05-09 | 2019-02-28 | Aldeyra Therapeutics Inc | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. |
| WO2018170476A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| BR112019024944A2 (pt) | 2017-05-26 | 2020-06-23 | Novassay Sa | Subunidade auxilária de canal de cálcio com porta de tensão alfa 2 delta e suas utilizações |
| AU2018348174A1 (en) | 2017-10-10 | 2020-04-23 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
| AU2019319740A1 (en) | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN114599397B (zh) * | 2019-10-25 | 2024-05-28 | 国立大学法人京都大学 | Tau蛋白病的预防或治疗剂 |
| CA3175856A1 (en) | 2020-05-13 | 2021-11-18 | Todd Brady | Pharmaceutical formulations and uses thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2503059A (en) * | 1950-04-04 | Nxchj | ||
| US2599000A (en) * | 1950-09-02 | 1952-06-03 | Smith Kline French Lab | Nu, nu-disubstituted-beta-halo-alkylamines |
| US3238215A (en) * | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
| IT1066857B (it) * | 1965-12-15 | 1985-03-12 | Acraf | Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione |
| US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| NL175059C (nl) * | 1974-02-23 | Boehringer Mannheim Gmbh | Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten. | |
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
| FR2421888A1 (fr) * | 1978-02-06 | 1979-11-02 | Synthelabo | Amides d'alkylene-diamines et leur application en therapeutique |
| IT1094076B (it) * | 1978-04-18 | 1985-07-26 | Acraf | Cicloalchiltriazoli |
| JPS56110665A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| US5084479A (en) * | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| GB9117716D0 (en) * | 1991-08-16 | 1991-10-02 | Lynxvale Ltd | Gaba derivatives and their therapeutic application |
| CZ286106B6 (cs) | 1992-05-20 | 2000-01-12 | Northwestern University | Analogy GABA a L-glutamové kyseliny |
| US5510381A (en) * | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| CA2244708A1 (en) | 1996-02-07 | 1997-08-14 | Justin S. Bryans | Novel cyclic amino acids as pharmaceutical agents |
| PL185991B1 (pl) | 1996-03-14 | 2003-09-30 | Warner Lambert Co | Nowe podstawione cykliczne aminokwasy i kompozycja farmaceutyczna |
| IL125364A0 (en) | 1996-03-14 | 1999-03-12 | Warner Lambert Co | Novel bridged cyclic amino acids and pharmaceutical compositions containing them |
| US6372792B1 (en) * | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| AU733896B2 (en) | 1996-10-23 | 2001-05-31 | Warner-Lambert Company | Substituted gamma aminobutyric acids as pharmaceutical agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| AU8668598A (en) * | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
| CU23048A3 (es) | 1997-10-27 | 2005-06-24 | Warner Lambert Co | Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos |
| YU33700A (sh) | 1997-12-16 | 2004-05-12 | Pfizer Products Inc. | Kombinacija efikasna u tretiranju impotencije |
| EP1475371A1 (en) | 1997-12-16 | 2004-11-10 | Warner-Lambert Company LLC | 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| EP1400526A3 (en) | 1997-12-16 | 2004-03-31 | Warner-Lambert Company LLC | ((cyclo)alkyl substituted)- gamma -aminobutyric acid derivatives (=Gaba analogues), their preparation and their use in the treatment of neurological disorders |
| CA2304967C (en) | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| KR20010043831A (ko) * | 1998-05-26 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물 |
| EP1094803A2 (en) * | 1998-07-09 | 2001-05-02 | Warner-Lambert Company | Use of gaba-analogues for treating insomia |
| US5945424A (en) * | 1998-07-31 | 1999-08-31 | G & H Associates, Inc. | Treatment of periodic limb movement syndrome |
| KR20010075064A (ko) * | 1998-09-14 | 2001-08-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 분지쇄 알킬 피롤리딘-3-카르복실산 |
| DE60044160D1 (de) | 1999-04-08 | 2010-05-20 | Warner Lambert Co | Behandlung von Inkontinenz |
| WO2000066096A2 (en) * | 1999-04-30 | 2000-11-09 | Merab Lomia | Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders |
| WO2000067742A2 (en) * | 1999-05-05 | 2000-11-16 | Warner-Lambert Company | Use of gaba analogues for the modulation of substance p |
| HRP20020025A2 (en) | 1999-06-10 | 2003-12-31 | Warner Lambert Co | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| HN2000000224A (es) | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| CN1607201A (zh) * | 1999-12-08 | 2005-04-20 | 沃尼尔·朗伯公司 | 立体选择性地合成环状氨基酸的方法 |
| PT1255544E (pt) * | 2000-01-31 | 2007-06-15 | Genaera Corp | Inibidores da síntese da mucina. |
| GB0007884D0 (en) * | 2000-03-31 | 2000-05-17 | Pfizer Ltd | Diphenyl ether compounds useful in therapy |
| CA2409927A1 (en) * | 2000-05-31 | 2001-12-06 | Warner-Lambert Company | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| ATE390133T1 (de) * | 2000-06-26 | 2008-04-15 | Warner Lambert Co | Gabapentinanaloga für schlafstörungen |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| DK1317426T3 (da) | 2000-09-14 | 2006-01-09 | Gruenenthal Gmbh | Betal-thio-aminosyrer |
| CA2356829A1 (en) * | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| AR034160A1 (es) | 2000-09-30 | 2004-02-04 | Gruenenthal Gmbh | Sulfonilguanidinas, medicamentos que contienen estos compuestos y el uso de sulfonilguanidinas |
| DE10048715A1 (de) | 2000-09-30 | 2004-05-19 | Grünenthal GmbH | Verwendung von Aminosäure zur Behandlung von Schmerz |
| EP1343805A4 (en) | 2000-10-06 | 2005-07-20 | Xenoport Inc | COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION |
| US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| AU2002239257A1 (en) | 2000-11-17 | 2002-06-03 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| EP1337271B1 (en) * | 2000-11-30 | 2004-11-03 | Pfizer Products Inc. | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| ATE460392T1 (de) | 2001-04-19 | 2010-03-15 | Warner Lambert Co | Kondensierte bizyklische oder trizyklische aminosäuren |
| JP2004534764A (ja) * | 2001-05-25 | 2004-11-18 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 液状医薬組成物 |
| PT1404324E (pt) | 2001-06-11 | 2008-03-05 | Xenoport Inc | Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida |
| ITMI20011308A1 (it) | 2001-06-21 | 2002-12-21 | Nicox Sa | Farmaci per il dolore cronico |
| NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
-
2003
- 2003-11-27 CA CA002451267A patent/CA2451267A1/en not_active Abandoned
- 2003-12-02 US US10/726,878 patent/US7432299B2/en not_active Expired - Fee Related
- 2003-12-03 MX MXPA05006318A patent/MXPA05006318A/es unknown
- 2003-12-03 CN CNB2003801047024A patent/CN100367946C/zh not_active Expired - Fee Related
- 2003-12-03 AU AU2003303038A patent/AU2003303038B2/en not_active Ceased
- 2003-12-03 MX MXPA05005665A patent/MXPA05005665A/es unknown
- 2003-12-03 WO PCT/IB2003/005669 patent/WO2004054559A1/en not_active Ceased
- 2003-12-03 CA CA002509600A patent/CA2509600A1/en not_active Abandoned
- 2003-12-03 BR BR0316753-4A patent/BR0316753A/pt not_active IP Right Cessation
- 2003-12-03 PL PL377729A patent/PL377729A1/pl not_active Application Discontinuation
- 2003-12-03 CN CNA2003801059680A patent/CN1726015A/zh active Pending
- 2003-12-03 WO PCT/IB2003/005682 patent/WO2004054563A1/en not_active Ceased
- 2003-12-03 AU AU2003303037A patent/AU2003303037A1/en not_active Abandoned
- 2003-12-03 PL PL377656A patent/PL377656A1/pl not_active Application Discontinuation
- 2003-12-03 CN CNA200710110291XA patent/CN101283995A/zh active Pending
- 2003-12-03 EP EP03775689A patent/EP1572183A1/en not_active Withdrawn
- 2003-12-03 CA CA002509611A patent/CA2509611A1/en not_active Abandoned
- 2003-12-03 AU AU2003283708A patent/AU2003283708A1/en not_active Abandoned
- 2003-12-03 NZ NZ566452A patent/NZ566452A/en not_active IP Right Cessation
- 2003-12-03 NZ NZ539971A patent/NZ539971A/en unknown
- 2003-12-03 JP JP2004560041A patent/JP2006515587A/ja not_active Withdrawn
- 2003-12-03 CN CNA2003801059657A patent/CN1726022A/zh active Pending
- 2003-12-03 CN CNA2003801060137A patent/CN1726023A/zh active Pending
- 2003-12-03 WO PCT/IB2003/005640 patent/WO2004054577A1/en not_active Ceased
- 2003-12-03 CN CNA2008102138044A patent/CN101417129A/zh active Pending
- 2003-12-03 CN CNB2003801052910A patent/CN100430048C/zh not_active Expired - Fee Related
- 2003-12-03 JP JP2004560036A patent/JP2006511527A/ja active Pending
- 2003-12-03 KR KR1020057010548A patent/KR100703103B1/ko not_active Expired - Fee Related
- 2003-12-03 EP EP03813228A patent/EP1572172A1/en not_active Ceased
- 2003-12-03 BR BR0317273-2A patent/BR0317273A/pt not_active IP Right Cessation
- 2003-12-03 KR KR1020057010589A patent/KR20050085537A/ko not_active Ceased
- 2003-12-03 CN CNA2003801060090A patent/CN1726021A/zh active Pending
- 2003-12-09 US US10/731,605 patent/US20040132636A1/en not_active Abandoned
- 2003-12-10 MY MYPI20034741A patent/MY140525A/en unknown
- 2003-12-12 TW TW092135262A patent/TWI286934B/zh not_active IP Right Cessation
- 2003-12-12 US US10/735,398 patent/US20040143014A1/en not_active Abandoned
- 2003-12-12 TW TW092135260A patent/TW200412241A/zh unknown
-
2005
- 2005-05-13 ZA ZA200503862A patent/ZA200503862B/en unknown
- 2005-05-13 ZA ZA200503861A patent/ZA200503861B/en unknown
- 2005-05-13 ZA ZA200503863A patent/ZA200503863B/en unknown
- 2005-05-25 ZA ZA200504271A patent/ZA200504271B/en unknown
- 2005-05-31 ZA ZA200504475A patent/ZA200504475B/en unknown
- 2005-06-09 ZA ZA200504724A patent/ZA200504724B/xx unknown
-
2007
- 2007-02-15 US US11/675,389 patent/US20070293570A1/en not_active Abandoned
- 2007-03-19 US US11/688,001 patent/US20070161707A1/en not_active Abandoned
- 2007-03-19 US US11/687,978 patent/US20070213401A1/en not_active Abandoned
- 2007-03-19 US US11/687,964 patent/US20070161706A1/en not_active Abandoned
- 2007-03-19 US US11/687,993 patent/US20070276039A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515587A5 (enExample) | ||
| JP5373405B2 (ja) | 選択的アンドロゲン受容体モジュレーター | |
| RU2306309C2 (ru) | Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний | |
| ES2544532T3 (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| JP2001521020A5 (enExample) | ||
| RU2008106058A (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| CN105120866B (zh) | 与毒性醛相关的疾病和治疗 | |
| JP2021176846A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| US20100004481A1 (en) | L-threonine derivatives of high therapeutic index | |
| JP2009524675A5 (enExample) | ||
| CA2514384A1 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
| JP2005531516A5 (enExample) | ||
| JP2006143737A5 (enExample) | ||
| JP2004501189A5 (enExample) | ||
| WO1993003013A1 (fr) | Derives d'indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant | |
| JP2018524304A5 (enExample) | ||
| JP2003503449A5 (enExample) | ||
| JP2010090149A5 (enExample) | ||
| JPWO2023099592A5 (enExample) | ||
| JP2006504738A5 (enExample) | ||
| JP2009517411A5 (enExample) | ||
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| WO1995001352A1 (en) | Thiazolidine derivative and medicine containing the same | |
| JP2005516035A5 (enExample) | ||
| JPS61257967A (ja) | ２−ピロリドン誘導体 |